The effectiveness of rehabilitation in vulvovaginal atrophy
Objective: to evaluate the effectiveness and safety of rehabilitation programmes in patients with vulvovaginal atrophy (VVA). Material and methods. The study involved 350 patients with VVA in surgical (n=140) and natural (n=140) menopause, the control group included 70 women without VVA. Patients wi...
Saved in:
Published in: | Farmakoèkonomika (Moskva. Online) Vol. 17; no. 2; pp. 200 - 211 |
---|---|
Main Authors: | , , , , , |
Format: | Journal Article |
Language: | English Russian |
Published: |
IRBIS LLC
01-08-2024
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Objective: to evaluate the effectiveness and safety of rehabilitation programmes in patients with vulvovaginal atrophy (VVA).
Material and methods. The study involved 350 patients with VVA in surgical (n=140) and natural (n=140) menopause, the control group included 70 women without VVA. Patients with VVA were distributed into groups receiving complex “active” rehabilitation (surgical menopause: group 1A, natural menopause: group 2A) and “passive” rehabilitation (surgical menopause: group 1B, natural menopause: group 2B). Body mass index (BMI), vaginal pH, carbohydrate profile with calculation of insulin resistance index (HOMA-IR), inflammatory markers leptin, interleukin-6, tumour necrosis factor alpha, serum magnesium, and safety profile with evaluation of adverse events related to rehabilitation measures were assessed over 24 months.
Results. BMI decreased significantly in groups 1A and 2A. Vaginal pH at 1-year follow-up decreased in groups 1A and 2A, but increased in groups 2A and 2B. BMI was higher than normal in all patients with VVA, as well as in the control group, demonstrating preobesity (groups 1A, 2A, control group) or first-degree obesity (initially in group 1B and throughout follow-up in group 2B). HOMA-IR initially reflected postoperative insulin resistance in groups 1A and 2A, but in those receiving complex “active” rehabilitation the dynamics of its reduction was the most pronounced. The concentration of inflammatory markers was initially increased compared to the control group and decreased over time in groups 1A and 1B, but only leptin levels reached the control group values by the end of the study. Serum concentration of magnesium levels was 0.71±0.12 mmol/l in group 1A, 0.71±0.10 mmol/l in group 2A, 0.76±0.08 mmol/l in group 1B, 0.72±0.17 mmol/l in group 2B (magnesium deficiency). When organic magnesium salts in combination with pyridoxine were supplemented in groups 1A and 1B, serum magnesium levels were restored to normal from the 3 rd month of follow-up. No adverse events were registered.
Conclusion. The personalised programme of complex “active” rehabilitation in patients with VVA is more effective than “passive” rehabilitation with comparable safety profile. Its implementation into routine practice will contribute to the improvement of the quality of health care for such patients. |
---|---|
AbstractList | Objective: to evaluate the effectiveness and safety of rehabilitation programmes in patients with vulvovaginal atrophy (VVA).Material and methods. The study involved 350 patients with VVA in surgical (n=140) and natural (n=140) menopause, the control group included 70 women without VVA. Patients with VVA were distributed into groups receiving complex “active” rehabilitation (surgical menopause: group 1A, natural menopause: group 2A) and “passive” rehabilitation (surgical menopause: group 1B, natural menopause: group 2B). Body mass index (BMI), vaginal pH, carbohydrate profile with calculation of insulin resistance index (HOMA-IR), inflammatory markers leptin, interleukin-6, tumour necrosis factor alpha, serum magnesium, and safety profile with evaluation of adverse events related to rehabilitation measures were assessed over 24 months.Results. BMI decreased significantly in groups 1A and 2A. Vaginal pH at 1-year follow-up decreased in groups 1A and 2A, but increased in groups 2A and 2B. BMI was higher than normal in all patients with VVA, as well as in the control group, demonstrating preobesity (groups 1A, 2A, control group) or first-degree obesity (initially in group 1B and throughout follow-up in group 2B). HOMA-IR initially reflected postoperative insulin resistance in groups 1A and 2A, but in those receiving complex “active” rehabilitation the dynamics of its reduction was the most pronounced. The concentration of inflammatory markers was initially increased compared to the control group and decreased over time in groups 1A and 1B, but only leptin levels reached the control group values by the end of the study. Serum concentration of magnesium levels was 0.71±0.12 mmol/l in group 1A, 0.71±0.10 mmol/l in group 2A, 0.76±0.08 mmol/l in group 1B, 0.72±0.17 mmol/l in group 2B (magnesium deficiency). When organic magnesium salts in combination with pyridoxine were supplemented in groups 1A and 1B, serum magnesium levels were restored to normal from the 3rd month of follow-up. No adverse events were registered.Conclusion. The personalised programme of complex “active” rehabilitation in patients with VVA is more effective than “passive” rehabilitation with comparable safety profile. Its implementation into routine practice will contribute to the improvement of the quality of health care for such patients. Objective: to evaluate the effectiveness and safety of rehabilitation programmes in patients with vulvovaginal atrophy (VVA). Material and methods. The study involved 350 patients with VVA in surgical (n=140) and natural (n=140) menopause, the control group included 70 women without VVA. Patients with VVA were distributed into groups receiving complex “active” rehabilitation (surgical menopause: group 1A, natural menopause: group 2A) and “passive” rehabilitation (surgical menopause: group 1B, natural menopause: group 2B). Body mass index (BMI), vaginal pH, carbohydrate profile with calculation of insulin resistance index (HOMA-IR), inflammatory markers leptin, interleukin-6, tumour necrosis factor alpha, serum magnesium, and safety profile with evaluation of adverse events related to rehabilitation measures were assessed over 24 months. Results. BMI decreased significantly in groups 1A and 2A. Vaginal pH at 1-year follow-up decreased in groups 1A and 2A, but increased in groups 2A and 2B. BMI was higher than normal in all patients with VVA, as well as in the control group, demonstrating preobesity (groups 1A, 2A, control group) or first-degree obesity (initially in group 1B and throughout follow-up in group 2B). HOMA-IR initially reflected postoperative insulin resistance in groups 1A and 2A, but in those receiving complex “active” rehabilitation the dynamics of its reduction was the most pronounced. The concentration of inflammatory markers was initially increased compared to the control group and decreased over time in groups 1A and 1B, but only leptin levels reached the control group values by the end of the study. Serum concentration of magnesium levels was 0.71±0.12 mmol/l in group 1A, 0.71±0.10 mmol/l in group 2A, 0.76±0.08 mmol/l in group 1B, 0.72±0.17 mmol/l in group 2B (magnesium deficiency). When organic magnesium salts in combination with pyridoxine were supplemented in groups 1A and 1B, serum magnesium levels were restored to normal from the 3 rd month of follow-up. No adverse events were registered. Conclusion. The personalised programme of complex “active” rehabilitation in patients with VVA is more effective than “passive” rehabilitation with comparable safety profile. Its implementation into routine practice will contribute to the improvement of the quality of health care for such patients. |
Author | Ivanov, А. Е. Blinov, D. V. Khlopkova, S. V. Ampilogova, D. М. Solopova, А. G. Bykovshchenko, G. К. |
Author_xml | – sequence: 1 givenname: D. М. orcidid: 0000-0002-3509-9501 surname: Ampilogova fullname: Ampilogova, D. М. organization: City Clinical Hospital No. 52 – sequence: 2 givenname: А. G. orcidid: 0000-0002-7456-2386 surname: Solopova fullname: Solopova, А. G. organization: Sechenov University – sequence: 3 givenname: D. V. orcidid: 0000-0002-3367-9844 surname: Blinov fullname: Blinov, D. V. organization: Sechenov University; Institute for Preventive and Social Medicine; Moscow Haass Medical Social Institute – sequence: 4 givenname: А. Е. orcidid: 0000-0003-1115-3144 surname: Ivanov fullname: Ivanov, А. Е. organization: Yudin City Clinical Hospital – sequence: 5 givenname: S. V. orcidid: 0000-0003-2918-9401 surname: Khlopkova fullname: Khlopkova, S. V. organization: Vorokhobov City Clinical Hospital No. 67 – sequence: 6 givenname: G. К. surname: Bykovshchenko fullname: Bykovshchenko, G. К. organization: Sechenov University |
BookMark | eNpd0M1KAzEQwPEgCtaPd9gHcOtkk90keBI_CwUveg6zycTGbjeSXQt9e1tbevCUIQz_gd8FO-1TT4zdcJhypaS5rUBBKQ2Y24B5hctEy9SnVVzitIJKTqtan7DJYUuI0-MM5pxdD0NsQUolGqWrCbt7X1BBIZAb45p6GoYihSLTAtvYxRHHmPoi9sX6p1unNX7GHrsCx5y-F5srdhawG-j68F6yj-en94fXcv72Mnu4n5eOa6PLOvjGQ-Ma3xoyovZCE0BVByNVcJpCK2WrWk_gBHKvKnAVAveBSDg0jbhks33XJ_yy3zmuMG9swmj_PlL-tJjH6DqyGrwxPmhVGyclJ-R1gJq3fntetADb1uO-5XIahkzh2ONg_3ztTsvutOx_X7vztVtf8QuM7HhC |
Cites_doi | 10.17749/2077-8333/epi.par.con.2022.115 10.17749/2313-7347/ob.gyn.rep.2022.344 10.1007/s10549-021-06226-3 10.26442/20795696.2020.6.200485 10.1097/GME.0000000000001496 10.25207/1608-6228-2023-30-5-41-53 10.17749/2313-7347/ob.gyn.rep.2022.318 10.17749/2313-7347/ob.gyn.rep.2023.426 10.26442/20795696.2022.4.201792 10.1186/s12941-020-0347-4 10.55453/rjmm.2022.125.1.7 10.1016/S0029-7844(96)00447-4 10.1097/GME.0000000000002195 10.1080/09513590.2018.1563883 10.17749/2313-7347/ob.gyn.rep.2023.392 10.1016/j.jcma.2011.08.014 10.17749/2313-7347/ob.gyn.rep.2022.371 10.17749/2077-8333/epi.par.con.2023.168 10.1016/j.ejogrb.2022.08.012 10.3390/medicina58060770 10.17749/2313-7347/ob.gyn.rep.2022.345 10.1080/01443615.2020.1832973 10.17749/2313-7347/ob.gyn.rep.2023.391 10.17749/2070-4909/farmakoekonomika.2022.159 10.17749/2313-7347/ob.gyn.rep.2022.283 10.6118/jmm.2014.20.3.104 10.17749/2313-7347/ob.gyn.rep.2023.461 10.1080/13697137.2023.2225766 10.17749/2313-7347/ob.gyn.rep.2024.512 10.1097/AOG.0000000000003729 10.14341/7637 10.1080/13697137.2018.1446930 10.1016/j.maturitas.2023.03.007 |
ContentType | Journal Article |
DBID | AAYXX CITATION DOA |
DOI | 10.17749/2070-4909/farmakoekonomika.2024.258 |
DatabaseName | CrossRef Directory of Open Access Journals |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health |
EISSN | 2070-4933 |
EndPage | 211 |
ExternalDocumentID | oai_doaj_org_article_80d99df8759c441ea15f051bd6c63b00 10_17749_2070_4909_farmakoekonomika_2024_258 |
GroupedDBID | 642 AAFWJ AAYXX ADBBV ALMA_UNASSIGNED_HOLDINGS BCNDV CITATION GROUPED_DOAJ |
ID | FETCH-LOGICAL-c1898-5fd6d06c6db9e935d38e0025f947fc8efb44b7bde0c3a1d720c2a01dfee3ca963 |
IEDL.DBID | DOA |
ISSN | 2070-4909 |
IngestDate | Mon Oct 21 19:39:16 EDT 2024 Fri Nov 22 02:36:09 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English Russian |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1898-5fd6d06c6db9e935d38e0025f947fc8efb44b7bde0c3a1d720c2a01dfee3ca963 |
ORCID | 0000-0003-2918-9401 0000-0002-7456-2386 0000-0002-3509-9501 0000-0003-1115-3144 0000-0002-3367-9844 |
OpenAccessLink | https://doaj.org/article/80d99df8759c441ea15f051bd6c63b00 |
PageCount | 12 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_80d99df8759c441ea15f051bd6c63b00 crossref_primary_10_17749_2070_4909_farmakoekonomika_2024_258 |
PublicationCentury | 2000 |
PublicationDate | 2024-08-01 |
PublicationDateYYYYMMDD | 2024-08-01 |
PublicationDate_xml | – month: 08 year: 2024 text: 2024-08-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | Farmakoèkonomika (Moskva. Online) |
PublicationYear | 2024 |
Publisher | IRBIS LLC |
Publisher_xml | – name: IRBIS LLC |
References | ref13 ref35 ref12 ref34 ref15 ref14 ref31 ref30 ref11 ref33 ref10 ref32 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
References_xml | – ident: ref25 doi: 10.17749/2077-8333/epi.par.con.2022.115 – ident: ref29 doi: 10.17749/2313-7347/ob.gyn.rep.2022.344 – ident: ref35 doi: 10.1007/s10549-021-06226-3 – ident: ref20 – ident: ref12 doi: 10.26442/20795696.2020.6.200485 – ident: ref3 doi: 10.1097/GME.0000000000001496 – ident: ref24 doi: 10.25207/1608-6228-2023-30-5-41-53 – ident: ref26 doi: 10.17749/2313-7347/ob.gyn.rep.2022.318 – ident: ref32 doi: 10.17749/2313-7347/ob.gyn.rep.2023.426 – ident: ref22 – ident: ref6 doi: 10.26442/20795696.2022.4.201792 – ident: ref8 doi: 10.1186/s12941-020-0347-4 – ident: ref9 doi: 10.55453/rjmm.2022.125.1.7 – ident: ref23 doi: 10.1016/S0029-7844(96)00447-4 – ident: ref14 doi: 10.1097/GME.0000000000002195 – ident: ref2 doi: 10.1080/09513590.2018.1563883 – ident: ref31 doi: 10.17749/2313-7347/ob.gyn.rep.2023.392 – ident: ref21 doi: 10.1016/j.jcma.2011.08.014 – ident: ref16 doi: 10.17749/2313-7347/ob.gyn.rep.2022.371 – ident: ref33 doi: 10.17749/2077-8333/epi.par.con.2023.168 – ident: ref11 doi: 10.1016/j.ejogrb.2022.08.012 – ident: ref7 doi: 10.3390/medicina58060770 – ident: ref28 doi: 10.17749/2313-7347/ob.gyn.rep.2022.345 – ident: ref5 doi: 10.1080/01443615.2020.1832973 – ident: ref30 doi: 10.17749/2313-7347/ob.gyn.rep.2023.391 – ident: ref15 doi: 10.17749/2070-4909/farmakoekonomika.2022.159 – ident: ref27 doi: 10.17749/2313-7347/ob.gyn.rep.2022.283 – ident: ref19 doi: 10.6118/jmm.2014.20.3.104 – ident: ref34 doi: 10.17749/2313-7347/ob.gyn.rep.2023.461 – ident: ref13 doi: 10.1080/13697137.2023.2225766 – ident: ref17 doi: 10.17749/2313-7347/ob.gyn.rep.2024.512 – ident: ref4 doi: 10.1097/AOG.0000000000003729 – ident: ref18 doi: 10.14341/7637 – ident: ref1 doi: 10.1080/13697137.2018.1446930 – ident: ref10 doi: 10.1016/j.maturitas.2023.03.007 |
SSID | ssib044736782 ssj0002243826 ssib047418763 ssib053664050 |
Score | 2.3149545 |
Snippet | Objective: to evaluate the effectiveness and safety of rehabilitation programmes in patients with vulvovaginal atrophy (VVA).
Material and methods. The study... Objective: to evaluate the effectiveness and safety of rehabilitation programmes in patients with vulvovaginal atrophy (VVA).Material and methods. The study... |
SourceID | doaj crossref |
SourceType | Open Website Aggregation Database |
StartPage | 200 |
SubjectTerms | anxiety depression genitourinary syndrome of menopause gsm magnesium deficiency qol quality of life rehabilitation sexual dysfunction vulvar atrophy vulvovaginal atrophy vva |
Title | The effectiveness of rehabilitation in vulvovaginal atrophy |
URI | https://doaj.org/article/80d99df8759c441ea15f051bd6c63b00 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LSwMxEA7agwgiPrG-yMGja7NJNpsgHny09ORFBW9h8wKpdKXa_n5ndmutXrx4DeySfPkyMxky3xBy5pxR3nE4SCKpTKZcZ07pmAWtnWAV96XB4uThQ3n_rO_6KJOzaPWFb8JaeeAWuJ5mwZiQIKw2Hlx3rPIiAZFcUF4J4ExjfZlaukwBk6QshVrSaZeo0VJ-C00VQimIVNgiGwOOTOimNxuHM5BJw8waOUeLAuGR6S0GewkTzaM6jpqq4REqF3F5wbFj_JJfW5L_b_zUYItszgNMet0ubJusTKY7ZKPNztG26GiXXAI7aPuUY27taJ3o5IdqN30Z09n0dVbPqqZ1FsWsOWzKHnka9B9vh9m8jULmc210VqSgAgO4gjPRiCIIHTHUSUaWyeuYnJSudCEyL6o8lJx5XrE8pBiFr-CA7pPOuB7HA0KlliHxisOWNrI8DmZahiLKxA3YBt8lV18g2LdWLcPiLQNBtAiiRRDtbxAtgmgBxC65QeQW36L2dTMAjLBzRti_GHH4Hz85Ius4qfap3zHpfEym8YSsvofpacO0Tyu60Xg |
link.rule.ids | 315,782,786,866,2106,27933,27934 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effectiveness+of+rehabilitation+in+vulvovaginal+atrophy&rft.jtitle=Farmako%C3%A8konomika+%28Moskva.+Online%29&rft.au=Ampilogova%2C+D.+%D0%9C.&rft.au=Solopova%2C+%D0%90.+G.&rft.au=Blinov%2C+D.+V.&rft.au=Ivanov%2C+%D0%90.+%D0%95.&rft.date=2024-08-01&rft.issn=2070-4909&rft.eissn=2070-4933&rft.volume=17&rft.issue=2&rft.spage=200&rft.epage=211&rft_id=info:doi/10.17749%2F2070-4909%2Ffarmakoekonomika.2024.258&rft.externalDBID=n%2Fa&rft.externalDocID=10_17749_2070_4909_farmakoekonomika_2024_258 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2070-4909&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2070-4909&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2070-4909&client=summon |